Masimo Pronto-7â„¢ Receives Japanese and Canadian Regulatory Clearances
IRVINE, Calif., Aug. 29, 2011 /PRNewswire/ -- Masimo (NASDAQ: MASI) today announced the Japanese Ministry of Health Labor & Welfare (MHLW) and Health Canada regulatory clearances of Masimo Pronto-7™— enabling clinicians throughout Japan and Canada to quickly and conveniently measure total hemoglobin (SpHb®), SpO2, perfusion index, and pulse rate without removing a drop of blood.
Hemoglobin is one of the most commonly ordered tests in both the hospital and pre-hospital settings because it is critical to assessing blood loss following trauma, during surgery, and during hospital stay, as well as a patient's need for a blood transfusion. However, traditional lab testing requires a painful needle stick for the patient, time-consuming blood draws for the clinician, and typically provides delayed results. Masimo SpHb provides immediate real-time hemoglobin results that enable clinicians to more rapidly assess patients and detect and treat internal bleeding and low hemoglobin conditions earlier. And, although Masimo noninvasive and continuous total hemoglobin (SpHb) monitoring—commercially available in both Japan and Canada for over a year—is the preferred technology for hospitals and inpatient care centers, access to quick and easy spot-check hemoglobin measurements are valuable for a variety of healthcare assessment applications, including physician offices, outpatient care centers, and pre-hospital emergency settings.
Pronto-7 Makes Noninvasive Hemoglobin Testing a Reality in Japan and Canada
Japanese and Canadian regulatory clearances for the palm-sized, handheld Pronto-7 and noninvasive finger sensors make it possible for clinicians to take the pain and wait out of traditional hemoglobin blood testing. The Pronto-7 offers a breakthrough solution for measuring tot